Pharma Pulse 2/27/25: Tariff Impact on Generic Drug Market, FDA Approves Miudella & more
The latest news for pharma industry insiders.
Impact of Tariffs on the Generic Drug Market
In the first part of his video interview with Pharmaceutical Commerce Editor Nicholas Saraceno, Geoffrey Joyce, PhD, director of health policy at the Leonard D. Schaeffer Center for Health Policy & Economics at USC, outlines how the tax on goods coming from China and potential 25% tariff on pharmaceuticals could influence generic drug prices.
FDA Approves Miudella, First Hormone-Free, Copper IUD in Over 40 Years
The FDA approved a hormone-free, copper intrauterine device (IUD; Miudella; Sebela Pharmaceuticals) for the prevention of pregnancy in people of reproductive potential for up to 3 years.
Lilly to Spend $27 Billion to Bolster US Drug Manufacturing
Eli Lilly & Co. will spend at least $27 billion to build four US manufacturing plants, the latest company to brace for the potential impact of President Donald Trump’s tariffs.
The Estée Lauder Companies Inc. announced a collaboration with biotechnology company, Serpin Pharma, that aims to explore how their anti-inflammatory research can be applied in cosmetics to deliver significant skin care longevity benefits to consumers around the world.
Thank you Miranda Schmalfuhs and Pharmaceutical Executive for inviting me to discuss the impact of misinformation on public health. Patients certainly need more guidance in consuming information, especially when emotions are at stake.
Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs
